Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P00790 (PGA)
 2,475 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

In 11 patients, 12 arthrodeses of the ankle joint were performed by using absorbable self-reinforced poly-l-lactide (SR-PLLA) or polyglycolide (SR-PGA) screws. 8 patients had posttraumatic arthrosis, 3 rheumatoid arthritis, and 1 rigid flexion contracture of the ankle due to neuropathy. The average follow-up time was 14 (7-22) months. Solid fusion was achieved in 11 of 12 cases in 9(6-16) weeks.
 ...
PMID:Talocrural arthrodesis with absorbable screws, 12 cases followed for 1 year. 131 86

Although Elisa assays detecting rheumatoid factor's (RF) show high sensitivity and specificity, difficulties with IgA- and especially IgG-RF testing in ELISA systems, due to interaction from 'contaminating' IgM-RF is still thought to be a problem. Sera from 15 Rheumatoid Arthritis patients with high disease activity and high IgM-RF values were Dithiothreitol (DTT) treated. IgM-RF values were reduced to approximately zero in all tested sera. IgA-RF activity declined as expected, but also showed a statistically significant correlation between % reduction after DTT treatment and the IgM-RF value from the same serum sample. IgG-RF also decreased after DTT treatment, most pronounced for high IgG-RF values. A correlation (not statistically significant) between the % reduction in IgG-RF after DTT treatment and the IgM-RF value from the same serum sample was observed. Pepsin and Diethylammonium ethyl (DEAE) reduced the IgG-RF activity even more than after DTT treatment of the sera. Fractionation by Gel filtration of 8 serum samples showed that all the RF activity were found according to the 'first top' of the gel filtration curve.
 ...
PMID:ELISA estimations of rheumatoid factor IgM, IgA, and IgG in sera from RA patients with high disease activity. DTT treatment studies. 323 67

Antibodies to the (PGA) prostaglandin A were produced in rabbits immunized with a conjugate of PGE2 covalently linked to (BSA) bovine serum albumin by reaction with carbodiimide reagent. A radioimmunoassay was developed using dextran-coated charcoal to separate the free from antibody bound PGA1-3H. The sensitivity of the method was found to be 100 picograms/ml of plasma. Ethyl acetate was used for extraction of plasma and the various classes of PGs were separated by silicic acid column chromatography. Recovery of PGA1-3H throughout the entire procedure was 65-75%. The antibody showed progressively decreasing affinity to PGA2, PGA1, PGE2, PGE1, PGB2, and PGF2alpha, respectively. The mean plasma PGA level in adult males (N=13) was found to be 1.39 + or - 0.55 ng/ml, and 1.62 + or - 0.52 ng/ml in adult females (N=7). Corresponding plasma and serum samples were found to give essentially similar results. Plasma PGA levels in adult males treated with indomethacin for rheumatoid arthritis were 0.18 + or - 0.15 ng/ml (P 0.001 in comparison with the normal adult males). This method is sufficiently sensitive, precise, and rapid to allow the routine estimation of the PGAs in biological samples.
 ...
PMID:Radioimmunoassay of the A prostaglandins. 466 56

Antilymphocyte antibodies (ALA) in rheumatoid arthritis (RA) have increased reactivity with phytohemagglutinin (PHA) activated lymphoblasts which are known to have increased expression of Ia antigen. The present experiments suggest that part of this reactivity represents an Ia specificity of ALA. Fifteen of 18 RA sera tested were able to inhibit the binding of monoclonal anti-Ia antibodies as measured by a rosette method. RA sera did not inhibit the binding of other monoclonal antibodies: anti-OKT3, anti-OKT4, and anti-OKT8. The ability of RA sera to inhibit the binding of anti-Ia antibody was eliminated after absorption of the RA sera with an Ia positive human cell line (B35M) but not by an Ia negative line (MOLT4). Blocking of anti-Ia binding was greater in the IgG fraction of the RA sera but also occurred in the IgM fraction. Experiments including ultracentrifugation, pepsin digestion of RA sera, and preincubation of lymphoblasts with aggregated IgG demonstrated that Fc binding by RA sera was not a factor. Both monoclonal anti-Ia and anti-Ia heteroantiserum also had increased reactivity with lymphoblast target cells. Pepsin digested Fab fragments of the anti-Ia heteroantiserum were able to block the activity of cytotoxic RA serum. However, ALA cytotoxic to lymphoblasts did not correlate with anti-Ia by rosette method. Ia-specific ALA by rosette method was associated with donor variability but did not appear to be HLA-DR restricted. Ia-specific ALA did correlate with disease activity. These data suggest that anti-Ia activity is present in RA sera and may play an immunoregulatory role in this disease.
 ...
PMID:Ia specific antilymphocyte antibodies in rheumatoid arthritis. 634 Jun 99

Mouse peritoneal macrophages were stimulated by sera from patients with active rheumatoid arthritis (RA) to increased intracellular cathepsin B activity. By gel filtration of three RA sera, the stimulatory activity was found in the IgG and to a lesser extent in the IgM containing fraction. The DEAE-cellulose purified IgG preparations of five additional RA patients stimulated intracellular cathepsin B activity significantly above IgG from healthy controls. IgG and IgM antibodies to macrophages were detected in sera from RA patients but not from controls by indirect immunofluorescence (IIF) technique. Pepsin F (ab')2 fragments of IgG from the RA patients also gave clearcut membrane fluorescent staining of the macrophages which demonstrated the antibody nature of the binding. A good correlation between the cathepsin B assay and the IIF was found when serial dilutions of serum were compared.
 ...
PMID:A serum antibody in patients with rheumatoid arthritis stimulates cathepsin B activity in peritoneal mouse macrophages. 636 Apr 38

We studied biochemically the changes associated with aging and disease in the collagen of articular cartilages and menisci. Pepsin soluble and insoluble collagen were obtained by the method of Miller (1971) from the articular cartilages of seven healthy young and adult, six healthy aged subjects, and of six osteoarthritic and six rheumatoid arthritic patients. One portion of pathological cartilage was histologically examined to eliminate any possible contamination of the fibrous tissue and subchondral bone, and to classify the pathological findings. By the method of Miller, the pepsin soluble and insoluble collagen were also obtained from four adult and six aged menisci. Amino acid composition and carbohydrate contents were studied in insoluble collagen. The type of soluble collagen were analyzed with SDS disc electrophoresis. The amount of crosslinks in insoluble collagen was analyzed by the method of Masuda (1976) using automatic amino acid analyzer. The results obtained where shown as follow: 1) Solubility of collagen by pepsin decreased with aging on articular cartilages and menisci. In osteoarthritis and rheumatoid arthritis, the solubility of collagen by pepsin was different between the samples, and generally higher than that of collagen from the aged articular cartilages. 2) In respect to aldimine crosslinks of insoluble collagen, the dihydroxylysinonorleucine (DHLNL), hydroxylysinonorleucine (HLNL) and lysinonorleucine (LNL) increased with aging. DHLNL and HLNL were present in the nonreduced collagen in vitro. It was shown that the aldimine crosslinks had been already reduced in vivo. 3) The contents of carbohydrate of insoluble collagen from articular cartilage showed lower values than that of type II collagen as described previously. The hexosamine contents increased and those of uronic acid and hexose decreased with aging. In osteoarthritic and rheumatoid arthritic articular cartilages, the contents of uronic acid were lower than that of healthy aged group. The carbohydrate contents of menisci were similar to that of type I collagen. 4) concerning the type of collagen, healthy articular cartilages consisted of type II collagen. In collagen of aged cartilages and those of fibrillated and osteophytic cartilages in osteoarthritic and rheumatoid arthritic patients, the type II collagen were mixed with type I collagen ranging from 13.8% to 64.5%, although the analysis of articular cartilages in this study showed histological characteristics of hyaline cartilage. The type of soluble collagen in adult and aged menisci were composed of type I collagen in spite of aging.
 ...
PMID:[Biochemical study of human articular cartilage and meniscus on aging and joint disease (author's transl)]. 689 84

1. Function of synoviocytes and other cells in the synovium A. Histologic Considerations 1. Electron microscopic studies 2. In vivo and in vitro phagocytosis studies 3. Fluorescent antibody staining B. Culture techniques 1. Problems posed by study of isolated cells 2. Long-term explant cultures 3. Advantages of short-term incubations of synovial fragments 4. Isolation of immunoglobulins C. Non-Immunoglobulin Products of the Synovium 1. Products of normal synovium 2. Alterations induced by rheumatoid arthritis II. The Local Immune response in Rheumatoid Synovitis A. Evidence for Active Immune Stimulation 1. Meditators of cellular immunity in synovial fluid 2. Effect of synovectomy 3. Type and amount of immunoglobulin produced B. Local Commitment of Antibody Response 1. Effect of exogenous immunization 2. Rheumatoid factors. 3. Pepsin agglutinators C. 1. Relative enrichment for IgG-3 subclass 2. Increase in lambda-light chain composition III. Pathogenetic Considerations in Rheumatoid Arthritis A. Comparison of Rheumatoid versus Experimental Immune Synovitis 1. Chronic synovitis as a local immune response. 2. Role of cartilage complexes in substaining chronic synovitis B. Significance of the Restriction in the Immunoglobulin Response in Rheumatoid Arthritis 1. Analogy with other disease states in man 2. Common antigen in RA?
 ...
PMID:Protein synthesis in rheumatoid synovial tissue. 732 52

Rheumatoid arthritis patients were found to have CD4+ T cells that proliferate in response to autologous synovial fluid and plasma. T cell clones and polyclonal T cell lines were found to respond to antigen(s) eluted from protein A Sepharose and anti-human immunoglobulin (Ig) antibody Sepharose. The antigen(s) was further resolved to fractions that contained intact Ig or Ig heavy chain since the T cells responded to > 100 kDa and 40-60 kDa polypeptides derived from purified Ig under nonreducing and reducing conditions, respectively. These results indicated that the antigen(s) is either Ig heavy chain or Ig-binding proteins that copurify with Ig and Ig subunits. Pepsin and papain digestion of the antigenic fractions eluted from protein A destroyed the T cell reactivity. Since most Fab regions are resistant to these enzymes, further analyses are required to localize the antigenic epitope(s). The presence of Ig- or Ig-antigen complex-reactive T cells in arthritic joints implies that B cells expressing anti-Ig antibody (i.e. rheumatoid factor) may play an important role in antigen presentation to autoreactive T cells.
 ...
PMID:Joint-derived T cells in rheumatoid arthritis react with self-immunoglobulin heavy chains or immunoglobulin-binding proteins that copurify with immunoglobulin. 802 May 76

The aim of this work was to develop two logistic regression models capable of predicting physical and mental health related quality of life (HRQOL) among rheumatoid arthritis (RA) patients. In this cross-sectional study which was conducted during 2006 in the outpatient rheumatology clinic of our university hospital, Short Form 36 (SF-36) was used for HRQOL measurements in 411 RA patients. A cutoff point to define poor versus good HRQOL was calculated using the first quartiles of SF-36 physical and mental component scores (33.4 and 36.8, respectively). Two distinct logistic regression models were used to derive predictive variables including demographic, clinical, and psychological factors. The sensitivity, specificity, and accuracy of each model were calculated. Poor physical HRQOL was positively associated with pain score, disease duration, monthly family income below 300 US$, comorbidity, patient global assessment of disease activity or PGA, and depression (odds ratios: 1.1; 1.004; 15.5; 1.1; 1.02; 2.08, respectively). The variables that entered into the poor mental HRQOL prediction model were monthly family income below 300 US$, comorbidity, PGA, and bodily pain (odds ratios: 6.7; 1.1; 1.01; 1.01, respectively). Optimal sensitivity and specificity were achieved at a cutoff point of 0.39 for the estimated probability of poor physical HRQOL and 0.18 for mental HRQOL. Sensitivity, specificity, and accuracy of the physical and mental models were 73.8, 87, 83.7% and 90.38, 70.36, 75.43%, respectively. The results show that the suggested models can be used to predict poor physical and mental HRQOL separately among RA patients using simple variables with acceptable accuracy. These models can be of use in the clinical decision-making of RA patients and to recognize patients with poor physical or mental HRQOL in advance, for better management.
 ...
PMID:Logistic regression models for predicting physical and mental health-related quality of life in rheumatoid arthritis patients. 1856 85

During the past decade, the arena of polymer therapeutics has acquired considerable interest and accompanied by advanced designs and chemical properties of polymer-drug conjugates. Various polymers, such as poly (ethylene glycol) (PEG), N-(2-hydroxypropyl) methacrylamide (HPMA), poly(glycolic acid) (PGA) and poly(lactide-co-glycolide) (PLGA) have been used successfully for clinical utilization from decades. These polymers are used in combination of drugs in such a manner that they target the specific tissues and thus the toxicity of drugs to other tissues is reduced. Presently, numerous polymer drug conjugates are under clinical trial for treatment of various diseases including cancer, diabetes, AIDS, rheumatoid arthritis etc. Many protein-polymer conjugates have been approved by FDA for clinical use but till date, no polymer-synthetic drug conjugate is approved by FDA, although many of them are undergoing final phase of clinical trials. This review highlights the recent advancements in the polymer-drug conjugates for treatment of various diseases and their preclinical and clinical status.
 ...
PMID:Polymer Drug Conjugates: Recent Advancements in Various Diseases. 2689 41


1 2 Next >>